Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
ID: 332069Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/332069

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-124.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)," aimed at advancing research in assay development and the identification of neurotherapeutic agents for neurological or neuromuscular disorders. This initiative encourages applications for research grants that focus on developing in vitro and/or ex vivo assays and conducting iterative screening to identify potential therapeutic agents, ultimately facilitating projects to meet the entry criteria for the NIH Blueprint Neurotherapeutics Network. The program supports innovative approaches to address unmet medical needs in neurological research, with a budget cap of $499,000 annually and a maximum project duration of three years. Interested applicants can find more information and guidelines at the NIH website and should note that the application deadline is October 21, 2024. For inquiries, contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PAR-21-124-Full-Announcement.html
    PAR-21-124.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)," which focuses on assay development and the identification of neurotherapeutic agents for neurological or neuromuscular disorders. This initiative is designed to advance research projects to the entry criteria for the NIH Blueprint Neurotherapeutics Network. The funding mechanism utilized is the R61/R33 phased award, which supports both the development and validation of in vitro/ex vivo assays and the screening of candidate therapeutics. Key aspects include a budget cap of $499,000 annually, a maximum project duration of three years, and an emphasis on evidence-based, innovative approaches targeting unmet medical needs in neurological research. The application process requires precise adherence to guidelines and offers additional support for diverse teams and small businesses. NIH encourages collaborations with industry experts to enhance drug development prospects, ensuring that submitted applications demonstrate robust milestones and clear methodologies to facilitate effective evaluation and progression to later-stage translational efforts.
    Similar Opportunities
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, aimed at funding pharmacodynamic, pharmacokinetic, and in vivo efficacy studies for novel therapeutic agents targeting neurological and neuromuscular disorders. This funding opportunity encourages diverse organizations, including historically black colleges, tribal governments, and community-based organizations, to develop innovative therapeutic approaches that demonstrate significant improvements over existing treatments. With funding available up to $499,000 per year and a maximum of $750,000 over three years, applicants must adhere to rigorous scientific standards and collaborate with multidisciplinary teams. Interested parties should note that the application deadline is October 21, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the Department of Health and Human Services, is offering funding opportunities under the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, aimed at developing and validating animal models and human/animal ex vivo systems for neurological disorders. The primary objective is to enhance the translational relevance of these models to facilitate neurotherapeutic discovery, with applications invited for the R61/R33 phased award mechanism, which includes an R61 phase for model development and internal validation, followed by an R33 phase for external validation. This initiative is crucial for advancing neurological research and improving therapeutic efficacy predictions, with a total budget cap of $750,000 over three years for selected projects. Interested applicants must submit their proposals by October 21, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for any inquiries regarding the funding announcement.
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development," aimed at developing neurophysiological assays to enhance treatment strategies for mental disorders. This initiative seeks to support partnerships among neuroscientists to optimize and evaluate pharmacodynamic measures in both human subjects and relevant animal models, thereby improving the efficiency of preclinical and clinical trials. The UG3/UH3 cooperative agreement format will facilitate a two-phase approach, focusing first on feasibility and assay optimization, followed by comparative performance evaluations. Interested applicants can find more information and submit proposals by June 20, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (U01), aimed at supporting Investigational New Drug (IND)-enabling studies and clinical trial planning for innovative gene-based therapeutics targeting ultra-rare diseases affecting fewer than 6,000 individuals. The program seeks to advance promising therapeutic candidates through robust proof-of-concept data and facilitate the submission of IND applications to the FDA, thereby addressing significant unmet medical needs within the ultra-rare disease community. Eligible applicants include higher education institutions, nonprofits, and governmental agencies, with a project period not exceeding two years and application deadlines ranging from October 2023 to February 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided NIH link.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Blueprint Neurotherapeutics Network (BPN) for small molecule drug discovery and development targeting disorders of the nervous system. This initiative invites applications for cooperative agreements (UG3/UH3) from neuroscience investigators to advance their projects through various stages of drug development, including Discovery and Development phases, while collaborating with NIH-funded consultants and specialized contract research organizations (CROs). The program emphasizes the importance of innovative approaches to treating complex neurological conditions and requires adherence to Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). Interested applicants can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications due by August 18, 2026.
    Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)." This initiative aims to develop innovative neurophysiological and behavioral assays in animal models to enhance the therapeutic development pipeline for mental illnesses, focusing on optimizing measures that reflect clinically relevant brain processes. The program encourages research proposals that assess the sensitivity and specificity of these assays as screening tools and promote collaboration between preclinical and clinical studies to facilitate translation to human applications. Interested applicants can apply for grants up to $250,000, with the application deadline set for September 7, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html.
    Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This cooperative agreement program encourages investigators to conduct translational activities and clinical feasibility studies, including the implementation of clinical prototype devices, non-clinical safety testing, and obtaining necessary regulatory approvals. The program is structured in two phases: the UG3 phase focuses on non-clinical testing to secure regulatory approvals, while the UH3 phase supports clinical studies for market application. Eligible applicants include a diverse range of institutions, such as higher education, nonprofits, and small businesses, with a particular emphasis on underrepresented groups in science. Interested parties should note that the application deadline is September 27, 2024, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.